Search by property

This page provides a simple browsing interface for finding entities described by a property and a named value. Other available search interfaces include the page property search, and the ask query builder.

List of results

• Dardano et al. (2012): The effect of Ginkgo biloba extract on genotoxic damage in patients with differentiated thyroid carcinoma receiving thyroid remnant ablation with Iodine-131  + (Median (range): 42 (18-73) years)
• Van Zandwijk et al. (2000): EUROSCAN, a Randomized Trial of Vitamin A and N-Acetylcysteine in Patients With Head and Neck Cancer or Lung Cancer  + (Median (range): 61 (19-91), per arm: - vit. A: Median 61 (23-83) - NAC: 61 (28–86) - vit. A + NAC: 61 (23–83) - control: 60 (19-91))
• Niravath et al. (2019): Randomized controlled trial of high‐dose versus standard‐dose vitamin D3 for prevention of aromatase inhibitor‐induced arthralgia  + (Median (range): 64 (44-82))
• Nguyen et al. (2012): Randomized, Double-Blind, Placebo-Controlled Trial of Polyphenon E in Prostate Cancer Patients before Prostatectomy: Evaluation of Potential Chemopreventive Activities  + (Median Age (SD) per arm: Polyphenon E arm: 63.4 (5.9) years, placebo arm: 61.3 (5.7) years)
• Lian et al. (2014): Comparing the Effectiveness of Green Tea versus Topical Metronidazole Powder in Malodorous Control of Fungating Malignant Wounds in a Controlled Randomised Study  + (Median Age (min-max) per arm: Green tea arm: 55 (33-81) years, Metronidazole arm: 46 (35-81) years)
• Heggie et al. (2002): A phase III study on the efficacy of topical aloe vera gel on irradiated breast tissue  + (Median age (minimum-maximum) per arm: Aloe vera arm = 56 (28-89) years Placebo arm = 60 (34-84) years)
• Crew et al. (2012): Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with Hormone Receptor–Negative Breast Cancer  + (Median age (range) Poly E arm (all): 52 (36-64) years Placebo arm: 53.5 (40-59) years)
• Marucci et al. (2017): Double-blind randomized phase III study comparing a mixture of natural agents versus placebo in the prevention of acute mucositis during chemoradiotherapy for head and neck cancer  + (Median age (range) per arm: Aloe arm = 55 (30-74) Placebo arm = 59 (26-76))
• Lissoni et al. (2009): A Randomized Study of Chemotherapy versus Biochemotherapy with Chemotherapy plus Aloe arborescens in Patients with Metastatic Cancer  + (Median age (range) per arm: Aloe arm: 64 (61-77) years Control arm: 65 (58-79) years)
• Grimison et al. (2020): Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial  + (Median age (range): 55 (29-80) years)
• Ertekin et al. (2004): Zinc sulfate in the prevention of radiation-induced oropharyngeal mucositis: a prospective, placebo-controlled, randomized study  + (Median age: 54, Range: 18-71)
• Urashima et al. (2019): Effect of Vitamin D Supplementation on Relapse-Free Survival Among Patients With Digestive Tract Cancers The AMATERASU Randomized Clinical Trial  + (Median age: 66 years)
• Antunac et al. (2018): Vitamin D Supplementation and Survival in Metastatic Colorectal Cancer  + (Median age: 69 (24-79))
• Meyskens et al. (1995): Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial  + (Median per group: - intervention group: 51 - control group: 46)
• Sontakke et al. (2003): Ginger as an antiemetic in nausea and vomiting induced by chemotherapy: A randomized, cross-over, double blind study  + (Median: 47, Range: 24-70 years)
• Johansson et al. (2021): Vitamin D Supplementation and Disease-Free Survival in Stage II Melanoma: A Randomized Placebo Controlled Trial  + (Median: 51)
• Halyard et al. (2007): Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4)  + (Median: 54 years, Range: 31-88 years)
• Mix et al. (2015): Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck  + (Median: 57 years)
• Pace et al. (2003): Neuroprotective Effect of Vitamin E Supplementation in Patient Treated With Cisplatin Chemotherapy  + (Median: 57.5; range: 28-74 years)
• Pace et al. (2010): Vitamin E neuroprotection for cisplatin neuropathy  + (Median: 58.25; range: 28-74 years)
• Goossens et al. (2016): Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial  + (Median; range: 68; 46-90 years)

• Asfour et al. (2006): Effect of high-dose sodium selenite therapy on polymorphonuclear leukocyte apoptosis in non-Hodgkin's lymphoma patients  + (NI)
• Cruciani et al. (2012): L-Carnitine Supplementation for the Management of Fatigue in Patients With Cancer: An Eastern Cooperative Oncology Group Phase III, Randomized, Double-Blind, Placebo-Controlled Trial  + (NI)
• Dos Santos Martins (2016): Placebo-Controlled, Double-Blind, Randomized Study of a Dry Guarana Extract in Patients with Head and Neck Tumors Undergoing Chemoradiotherapy: Effects on Fatigue and Quality of Life  + (NI)
• Kessels et al. (2017): Topical Sinecatechins, 10%, Ointment for Superficial Basal Cell Carcinoma A Randomized Clinical Trial  + (NI)
• Sun et al. (2016): A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy  + (NI)
• Yekta et al. (2012): Ginger as a miracle against chemotherapy-induced vomiting  + (NI)

• Lin et al. (2010): Discrepancy of the effects of zinc supplementation on the prevention of radiotherapy-induced mucositis between patients with nasopharyngeal carcinoma and those with oral cancers: subgroup analysis of a double-blind, randomized study  + (Nasopharyngeal cancer: intervention arm: mean (SD): 50.60 (14.17) Nasopharyngeal cancer: placebo arm: mean (SD): 52.63 (11.28) Oral cancer: intervention arm: mean (SD): 50.48 (9.10) Oral cancer: placebo arm: mean (SD): 51.30 (10.81))
• Chung et al. (2016): Randomized Trial of Vitamin C/E Complex for Prevention of Radiation- Induced Xerostomia in Patients with Head and Neck Cancer  + (Overall age in years, mean (SD) = 58.8 (10.5); per arm: - intervention: 56.6 (11.3) - placebo: 61.6 (9.6))
• Rostock et al. (2013): Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients: A Four-Arm Randomized Trial on the Effectiveness of Electroacupuncture  + (Overall mean (SD): 52.7 (10.0) years; per arm: - electroacupuncture arm: 49.9 (9.6) - hydroelectric bath arm: 52.3 (11.3) - vit. B arm: 56.3 (11.1) - placebo arm: 52.0 (8.1))
• Konmun et al. (2017): A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy  + (Overall median (range) in years: 53 (19-81); per arm: - intervention arm: 52 (19-81) - placebo arm: 55 (37-79))
• Fallon et al. (2017) II: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies  + (Part A Mean (SD) age: 61.2 (11.2) years Part B Mean (SD) age per arm: Sativex = 61.4 (10.9) years Placebo = 61.6 (11.8) years)
• Mayne et al. (2001): Randomized Trial of Supplemental beta-Carotene to Prevent Second Head and Neck Cancer  + (Per group mean (SD) - intervention: 67.8 (9.8) - placebo: 67.9 (9.3))
• Dias et al. (2015): The chemopreventive effect of Ginkgo biloba extract 761 against cisplatin ototoxicity: a pilot study  + (Range 24–69 years)
• Sharp et al. (2010): A randomised, controlled trial of the psychological effects of reflexology in early breast cancer  + (Range 32-81 years; Mean 58.78 years (SD:10.31))
• Campos et al. (2011): Guarana (Paullinia cupana) Improves Fatigue in Breast Cancer Patients Undergoing Systemic Chemotherapy  + (Range: 22-70 years)
• Walsh et al. (2010): Use of alpha,25-dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma  + (Range: 45-92 Intervention arm: mean: 66 Control arm: mean: 63)
• Howells et al. (2011): Phase I randomised double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases - safety, pharmacokinetics and pharmacodynamics  + (SRT501 (resveratrol): 68.5(10.8) years Placebo: 64.3(6.35) years)
• Muecke et al. (2014): Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology: follow-up analysis of the survival data 6 years after cessation of randomization  + (Start of the original study (Muecke et al., 2010): mean (SD); range: 64.3 (10.1); 31–80 years)
• Keshavarzi et al. (2019): The effect of vitamin D and E vaginal suppositories on tamoxifen-induced vaginal atrophy in women with breast cancer  + (Vitamin D arm: mean (SD): 43.7 (3.9) vitamin E arm: mean (SD): 44.1 (4.6) placebo arm: mean (SD): 42.0 (6.3))
• Sanaati et al. (2016): Effect of Ginger and Chamomile on Nausea and Vomiting Caused by Chemotherapy in Iranian Women with Breast Cancer  + (n in the following age groups for ginger vs. chamomile vs. control: - 20-30 years: 1/1/1 - 31-40 years: 6/1/6 - 41-50 years: 7/12/7 - 51-60 years: 1/1/1 Range: 20-60 years)
• Kottschade et al. (2011): The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase 3 clinical trial  + (≤ 50 years: 39%, > 50 years: 61%)